Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Trial Profile

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs CAEL 101 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Aug 2017 According to a Fortress Biotech media release, Columbia filed a second provisional patent application with the USPTO to pursue additional method of treatment claims directed to surprising and positive outcomes observed from the phase 1b part of this trial.
    • 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to a Fortress Biotech media release.
    • 04 May 2017 According to a Fortress Biotech media release, company expects preliminary data from this trial is mid-2017, and full data by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top